4.7 Article

Dithiocarbazate-Zn(ii) complexes for photodynamic therapy and chemotherapy against lung cancer

Journal

INORGANIC CHEMISTRY FRONTIERS
Volume 10, Issue 22, Pages 6526-6536

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/d3qi01777j

Keywords

-

Ask authors/readers for more resources

This study synthesized a series of new Zn(II) complexes and found that one of the complexes showed good chemotherapeutic ability and induced cancer cell death through the generation of radicals under light irradiation, providing a new strategy for multimodal cancer therapy.
Combining photodynamic therapy with chemotherapy is a promising strategy for treating tumors. Herein, a series of new dithiocarbazate-Zn(ii) complexes, including [Zn-II(L1)(2)] Zn1, [Zn-II(L2)(2)] Zn2, [Zn-II(L3)(2)] Zn3, and [Zn-II(L4)(2)] Zn4, have been synthesized for chemotherapy and photodynamic therapy of lung cancer. These complexes can be used for live-cell fluorescence-based imaging, are photostable, and exhibit hemolysis comparable to cisplatin. Among them, complex Zn3 shows good chemotherapeutic ability, and its chemotherapeutic mechanism relies on multiple pathways. At the same time, complex Zn3 generates superoxide anion radicals (O-2(-)) under light irradiation, leading to cancer cell death through photodynamic therapy. Its remarkable anticancer effect is achieved through multimodal photodynamic therapy/chemotherapy. This study paves the way for the use of novel Zn(ii) complexes as anticancer agents, providing new strategies for multimodal cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available